PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07D 487/04, 471/04, A61K 31/415, 31/44, 31/505, 31/55, A61P 7/02 // (C07D 487/04, 231:00, 239:00) (C07D 487/04, 231:00, 237:00) (C07D 487/04, 223:00, 231:00) (C07D 471/04, 211:00, 231:00)

A1

(11) International Publication Number: **WO 00/39131**

(43) International Publication Date: 6 July 2000 (06.07.00)

(21) International Application Number: PCT/US99/30316

(22) International Filing Date: 17 December 1999 (17.12.99)

(30) Priority Data:

60/113,628	23 December 1998 (23.12.98)	US
60/127,633	2 April 1999 (02.04.99)	US

(71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; Chestnut Run Plaza, 974 Centre Road, Wilmington, DE 19807 (US).

(72) Inventors: FEVIG, John, M.; 987 Church Road, Lincoln University, PA 19352 (US). CACCIOLA, Joseph; 105 Pattie Drive, Newark, DE 19702 (US). CLARK, Charles, G.; 4 Glenview Place, Cherry Hill, NJ 08034 (US). LAM, Patrick, Yuk, Sun; 6 Ridgeway Drive, Chadds Ford, PA 19317 (US). PINTO, Donald, J., P.; 39 Whitson Drive, Newark, DE 19702 (US). PRUITT, James, R.; 237 Skycrest Drive, Landenberg, PA 19350 (US). ROSSI, Karen, A.; 120A Embery Court, Newark, DE 19711 (US).

(74) Agent: FERGUSON, Blair, F.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS

(57) Abstract

The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.